0EAP.LSE Euroapi
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0EAP.LSE undervalued?
Graham numberThe Graham number of Euroapi cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Euroapi fundamental analysis
No fundamental analysis for Euroapi yet.
Euroapi stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Euroapi
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostag…
Full company profileFinancial statements of Euroapi are not available yet.
Euroapi dividends
Euroapi has not paid dividends in the last 4 fiscal years.
Who owns Euroapi
- Insiders 34.84%
- Institutions 35.58%
- Public & others 29.58%
- Free float 50.8M
Euroapi company profile
- Company name
- Euroapi
- Ticker
- 0EAP.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 32 rue Alexandre Dumas, Paris, France, 75011
- Phone
- 33 1 23 45 67 89
- Website
- euroapi.com
About Euroapi
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Euroapi management
10- Mr. David SeignolleChief Executive Officer · born 1983
- Mr. Olivier FalutChief Financial Officer
- Mr. Jean-Francois BlancChief Operating Officer
- Sophie PalliezHead of Investor Relations
- Ms. Marion SantinChief Legal, Compliance, & IP Officer
- Ms. Raphaele HauzyChief People Officer
- Mr. Frederic LelievreChief Quality Officer
- Ms. Sylvia Cabrillac-RivesChief Strategy Officer
- Mr. Frederic RobertChief Commercial Officer
- Mr. Laurent PetitChief Research & Development Officer